AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Achieve Life Sciences Statistics
Share Statistics
Achieve Life Sciences has 34.39M shares outstanding. The number of shares has increased by 0.4% in one year.
Shares Outstanding | 34.39M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.14% |
Owned by Institutions (%) | n/a |
Shares Floating | 27.60M |
Failed to Deliver (FTD) Shares | 3.56K |
FTD / Avg. Volume | 2.23% |
Short Selling Information
The latest short interest is 2.93M, so 8.52% of the outstanding shares have been sold short.
Short Interest | 2.93M |
Short % of Shares Out | 8.52% |
Short % of Float | 10.62% |
Short Ratio (days to cover) | 24.46 |
Valuation Ratios
The PE ratio is -2.74 and the forward PE ratio is -4.04.
PE Ratio | -2.74 |
Forward PE | -4.04 |
PS Ratio | 0 |
Forward PS | 3.5 |
PB Ratio | -56.41 |
P/FCF Ratio | -3.33 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Achieve Life Sciences Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of -11.51.
Current Ratio | 0.82 |
Quick Ratio | 0.82 |
Debt / Equity | -11.51 |
Total Debt / Capitalization | 109.52 |
Cash Flow / Debt | -1.47 |
Interest Coverage | -9.55 |
Financial Efficiency
Return on equity (ROE) is 20.59% and return on capital (ROIC) is -178.3%.
Return on Equity (ROE) | 20.59% |
Return on Assets (ROA) | -1.54% |
Return on Capital (ROIC) | -178.3% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.36M |
Employee Count | 22 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -25.88% in the last 52 weeks. The beta is 1.58, so Achieve Life Sciences 's price volatility has been higher than the market average.
Beta | 1.58 |
52-Week Price Change | -25.88% |
50-Day Moving Average | 4.18 |
200-Day Moving Average | 4.59 |
Relative Strength Index (RSI) | 26.85 |
Average Volume (20 Days) | 160.16K |
Income Statement
Revenue | n/a |
Gross Profit | -228.00K |
Operating Income | -27.25M |
Net Income | -29.82M |
EBITDA | -26.73M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.5 |
Balance Sheet
The company has 15.55M in cash and 16.73M in debt, giving a net cash position of -1.19M.
Cash & Cash Equivalents | 15.55M |
Total Debt | 16.73M |
Net Cash | -1.19M |
Retained Earnings | -165.75M |
Total Assets | 47.92M |
Working Capital | 38.81M |
Cash Flow
In the last 12 months, operating cash flow was -24.48M and capital expenditures -21.00K, giving a free cash flow of -24.50M.
Operating Cash Flow | -24.48M |
Capital Expenditures | -21.00K |
Free Cash Flow | -24.50M |
FCF Per Share | -1.24 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ACHV does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -47.62% |
FCF Yield | -22.65% |
Analyst Forecast
The average price target for ACHV is $12, which is 281% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 281% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Stock Splits
The last stock split was on Jul 31, 2020. It was a backward split with a ratio of 1:20.
Last Split Date | Jul 31, 2020 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -2.15 |
Piotroski F-Score | 3 |